Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAnti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide
Description: Blocking peptide (unphosphorylated) for anti-phospho-GluR1 (Ser831) (Cat. No. 2041)
Biological Activity
Synthetic peptide (LIPQQSINEAI[K]) corresponding to amino acids 826-836 of rat mature GluR1 (Accession No. P19490), with a lysine added to the C-terminus for conjugation. Depletion peptide used during purification of anti-phospho-GluR1 (Ser831) (Cat. No. 2041).
Technical Data
| M. Wt | 1352.76 |
| Formula | C60H104N16O19 |
| Sequence | LIPQQSINEAIK |
| Storage | Desiccate at -20°C |
| Smiles | [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References
References are publications that support the biological activity of the product.
View Related Products by Target
Keywords: Anti-phospho-GluR1 (Ser 831) unphosphoylated blocking peptide, Anti-phospho-GluR1 (Ser 831) unphosphoylated blocking peptide supplier, Blocking, peptides, unphosphorylated, anti-phospho-GluR1, Ser831, Glutamate, AMPA, Receptors, iGluR, Ionotropic, Anti-phospho-GluR1(Ser831), unphosphoylated, blocking, 2336, Tocris Bioscience
Citations for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide
Citations are publications that use Tocris products.
Currently there are no citations for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide.
Reviews for Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide
There are currently no reviews for this product. Be the first to review Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide and earn rewards!
Have you used Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.